Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 480 participants.

Also called NCT07181382

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 480 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07181382
  • EU CT 2025-521777-13-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Israel (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT07181382. Randomized; double masking; primary purpose treatment. Start 2026-02 (anticipated); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Acronym
SERANATA
Condition
Pulmonary Hypertension Associated With Interstitial Lung Disease
Intervention (Drug)
Placebo
Intervention (Drug)
Seralutinib
Intervention (Device)
Generic Dry Powder Inhaler
Lead sponsor
GB002, Inc. (class: industry)
Collaborator
Chiesi Farmaceutici S.p.A. (class: industry)

Record details

Record id
cardio:ct-nct07181382
Content hash
13f66fcee53ea5fd9c68210e39077c11f3f33dd9dbb422fe15bc5329e26462b3